I'm part of an experiment using Victoza on type 1s. I believe it shuts down glucagon. I'm a biochemist so I should know but I haven't looked it up yet. I've only been on it three days so I don't really have any reports yet, but I wondered what others have experienced.

Views: 71

Reply to This

Replies to This Discussion

Hahaha! I'm a biochemist as well, and am too lazy to do so :) I do know of some Type 1s who are on it. However, it is a controversial drug as it has been linked to thyroid disease. Thanks to Paula Dean, I'm sure it will stir up even more controversy.

Victoza has not been approved for use in T1s. It is however being prescribed by some doctors for T1 use, primarily for weight loss (and some might argue for better blood sugars). Bernstein apparenty has been prescribing Byetta for T1s with some success, and I believe he now has moved on to Victoza as it is just as effective with only one injection per day.

Byetta, Victoza and now Bydureon are GLP-1 analogs. They immitate the incretin signaling that ocurrs when we eat. Normally, one of the things that incretins signal is the generation of the hormone Amylin. Amylin is produced by the beta cells and counteracts the normal production of glucose by your liver as well as slowing the gastric emptying and reducing food intake. Amylin production is destroyed in T1s. Symlin actually is a synthetic form of Amylin and is intended to replace it's action in T1s. Apparently the GLP-1 analogs are able to achieve some of the same benefits (as Symlin) for T1s although the mechanism is apparently not well understood.

I'd like to hear more about the experiment you are taking part in. I hope it is a clinical trial.

ps. Victoza has been linked to higher rates of thyroid cancer in rats and mice, although the effect has as yet not been observed in humans. It is not recommended for anyone who has biomarkers suggesting thyroid cancer. The medication is actually highly regarded by many, but as always we have to be alert to downsides.




From the Diabetes Hands Foundation blog...

DHF receives $200,000 grant from Novo Nordisk

Grant given to support programs aimed at bringing together people touched by diabetes for positive change BERKELEY, CA: December 4, 2014 – Diabetes Hands Foundation (DHF) has received a grant of US$200,000 from Novo Nordisk to support programs aimed at Read on! →

Guest Post: World Diabetes Day 2014 on Twitter… sifting through the data

At Symplur we track hashtags, keywords, user accounts, and pretty much anything else on Twitter that has to do with healthcare. We collect the data and then build countless ways to slice it up so that we’re able to better Read on! →

Diabetes Hands Foundation Team


Manny Hernandez
(Co-Founder, Editor, has LADA)

Emily Coles
(Head of Communities, has type 1)

Mila Ferrer
(EsTuDiabetes Community Manager, mother of a child with type 1)

Mike Lawson
(Head of Experience, has type 1)

Corinna Cornejo
(Development Manager, has type 2)

Desiree Johnson  (Administrative and Programs Assistant, has type 1)


Lead Administrator

Brian (bsc) (has type 2)


Lorraine (mother of type 1)
Marie B (has type 1)

DanP (has Type 1)

Gary (has type 2)

David (has type 2)


LIKE us on Facebook

Spread the word


This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.

© 2014   A community of people touched by diabetes, run by the Diabetes Hands Foundation.

Badges  |  Contact Us  |  Terms of Service